GHR is honored to provide $1 million in support of the Coronavirus Immunotherapy Consortium (CoVIC), a global partnership headquartered at the La Jolla Institute for Immunology (LJI). Led by Dr. Erica Ollmann Saphire, Ph.D., a professor in LJI’s Center for Infectious Disease and Vaccine Research, CoVIC aims to accelerate the discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2, the virus that causes COVID-19.
“As the COVID-19 pandemic has shown clearly, infectious disease anywhere becomes infectious disease everywhere. Until a vaccine becomes available, we need a way of giving people immediate immunity,” says Dr. Saphire, “and antibody therapy is the way to do it. The support of GHR will help us expand and accelerate the analysis of antibodies from people who have recovered from COVID-19, to understand how they work and deliver the best ones across the globe.”